CVS Health Reaches Insulin Pricing Settlement with FTC, to Conclude in Weeks

CVS Health has reached a proposed settlement agreement with the Federal Trade Commission (FTC) on insulin pricing. The deal, modeled on a similar agreement with rival pharmacy benefit manager Express Scripts, requires CVS to curb rebate pricing and adopt more transparency. The settlement is expected to conclude in the coming weeks. Analysts say the changes will have a minimal impact on CVS' earnings and remove regulatory risks for the company.